Pancreatoduodenectomy: the Metabolic Syndrome is Associated with Preventable Morbidity and Mortality

Background Patients with metabolic syndrome (MS) may have increased perioperative morbidity and mortality. The aim of this analysis was to investigate the association of MS with mortality, serious morbidity, and pancreatectomy-specific outcomes in patients undergoing pancreatoduodenectomy (PD). Methods Patients with MS who underwent PD were selected from the 2014–2018 ACS-NSQIP pancreatectomy-specific database. MS was defined as obesity (BMI ≥ 30 kg/m 2 ), diabetes, and hypertension. Demographics and outcomes were compared by χ 2 and Mann–Whitney tests, and adjusted odds ratios from multivariable logistic regression assessed the association between MS and primary outcomes. Results Of 19,054 patients who underwent PD, 7.3% ( n = 1388) had MS. On univariable analysis, patients with MS had significantly worse outcomes ( p < 0.05): 30-day mortality (3% vs 1.8%), serious morbidity (26% vs 23%), re-intubation (4.9% vs 3.5%), pulmonary embolism (2.0% vs 1.1%), acute renal failure (1.5% vs 0.9%), cardiac arrest (1.9% vs 1.0%), and delayed gastric emptying (18% vs 16.5%). On multivariable analysis, 30-day mortality was significantly increased in patients with MS (aOR: 1.53, p < 0.01). Conclusion Metabolic syndrome is associated with increased morbidity and mortality in patients undergoing pancreatoduodenectomy. The association with mortality is a novel observation. Perioperative strategies aimed at reduction and/or mitigation of cardiac, pulmonary, thrombotic, and renal complications should be employed in this population given their increased risk.